Clinical trial NCT06844539: taRgeting bEtA-Cell Function To achIeVe Remission of Type 2 diAbeTEs
Official title: Targeting Beta-cell Function to Achieve Remission of Type 2 Diabetes (REACTIVATE). An Open-label, Single-centre, Randomised, Parallel Study to Assess the Efficacy, Safety and Utility of Fully Closed-loop Insulin Delivery in Achieving Remission of Diabetes Compared to Standard Therapy With a Glucose Sensor in Adults With Recent Onset Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Type 2 Diabetes
Keywords: Remission
closed-loop
Lead sponsor: University of Cambridge
Sponsor class: OTHER
Collaborators: name: Cambridge University Hospitals NHS Foundation Trust
First posted: 2025-02-25
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The main objective of the REACTIVATE study is to investigate whether a period of intensive insulin therapy using closed-loop technology, when combined with diet and lifestyle education, can restore beta-cell function and achieve remission of recent-onset type 2 diabetes.

This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes. The primary outcome is the number of participants achieving remission of diabetes at 52 weeks, defined as HbA1c below 48mmol/mol after 12 or more weeks off all diabetes medications.

Other key outcomes include area under the curve for C-peptide and glucose during mixed meal tolerance test, the proportion of time spent with glucose levels within and above the target glucose range and mean sensor glucose as recorded by glucose sensor at 52 weeks.

Safety evaluation comprises severe hypoglycaemic episodes, and other adverse and serious adverse events. Utility and human factors outcomes include glucose sensor and closed-loop usage, questionnaires and semi-structured interviews.

Detailed description: This is a single-centre, open-label, randomised, parallel design study comparing up to 12 weeks of fully closed-loop insulin delivery to standard care with a glucose sensor in adults with recent-onset type 2 diabetes.

Recruitment will target up to 56 participants to allow for drop-outs. Participants will be recruited from outpatient clinics at Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, local GP surgeries, social media advertising or other established practices at the centre. Written informed consent will be obtained from all participants before any study related activities.

After obtaining informed consent, the baseline visit (including mixed meal tolerance test) and a 2-3 week run-in period, participants will be randomised to either 12 weeks use of fully closed-loop insulin delivery or 12 weeks during which they will apply their standard diabetes therapy with a glucose sensor. Participants in both groups will receive diet and lifestyle advice with specific focus on the impact of diet and lifestyle choices on glucose sensor readings and trends.

Following the 12 weeks intervention period (and repeat mixed meal tolerance test) all participants will continue with standard diabetes therapy for nine months of follow-up (and final mixed meal tolerance test). Diabetes therapies will be adjusted every 3 months based on HbA1c.

The study includes up to 5 visits and 6 telephone/email contacts. Visits 2 and 3 may be combined. All participants will continue to be seen by their clinical team at frequencies as appropriate in line with usual clinical practice. All study visits will be scheduled in addition to routine clinical visits and will be performed by the research team. Maximum time in the study is 56 weeks.

Eligibility criteria: Inclusion Criteria:

* Aged 18 years and older
* Type 2 diabetes diagnosed \>6 months and ≤5 years ago
* Treatment with glucose lowering medication for at least 3 months
* HbA1c \>48 mmol/mol on analysis from local laboratory or equivalent
* Willing to wear study devices and follow study instructions
* Capacity to consent to participate in the study

Exclusion Criteria:

* Type 1 diabetes
* Current use of insulin pump
* Current use of any closed-loop system
* Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician
* Known or suspected allergy against insulin
* Pregnancy, planned pregnancy, or breast feeding
* Severe visual or hearing impairment
* Medically documented allergy towards the adhesive of plasters
* Serious skin diseases located at places of the body potentially used for localisation of the glucose sensor
* Drug or alcohol misuse
* Group 2 driving licence holder

Primary outcomes:
measure: The number of participants achieving remission of diabetes at 52 weeks
timeFrame: 52 weeks
Secondary outcomes:
measure: Mixed meal tolerance test (MMTT) area under the curve for C-peptide
timeFrame: 12 weeks
measure: Mixed meal tolerance test (MMTT) area under the curve for C-peptide
timeFrame: 52 weeks
measure: Mixed meal tolerance test (MMTT) area under the curve for glucose
timeFrame: 12 weeks
measure: Mixed meal tolerance test (MMTT) area under the curve for glucose
timeFrame: 52 weeks
measure: Proportion of time spent in tight target glucose range (3.9 to 7.8mmol/l)
timeFrame: 12 weeks
measure: Proportion of time spent in tight target glucose range (3.9 to 7.8mmol/l)
timeFrame: 52 weeks
measure: Proportion of time spent in target glucose range (3.9 to 10.0mmol/l)
timeFrame: 12 weeks
measure: Proportion of time spent intarget glucose range (3.9 to 10.0mmol/l)
timeFrame: 52 weeks
measure: Proportion of time spent below target glucose range (<3.9mmol/l)
timeFrame: 12 weeks
measure: Proportion of time spent below target glucose range (<3.9mmol/l)
timeFrame: 52 weeks
measure: Proportion of time spent above target glucose range (>10.0mmol/l)
timeFrame: 12 weeks
measure: Proportion of time spent above target glucose range (>10.0mmol/l)
timeFrame: 52 weeks
measure: Mean sensor glucose
timeFrame: 12 weeks
measure: Mean sensor glucose
timeFrame: 52 weeks
measure: Glycated haemoglobin
timeFrame: 12 weeks
measure: Glycated haemoglobin
timeFrame: 52 weeks
measure: Blood pressure
timeFrame: 12 weeks
measure: Blood pressure
timeFrame: 52 weeks
measure: Body weight
timeFrame: 12 weeks
measure: Body weight
timeFrame: 52 weeks
measure: Number of diabetes medications
timeFrame: 52 weeks
Other outcomes:
Locations:
city: Cambridge
country: United Kingdom
facility: Addenbrooke's Hospital NHS Foundation Trust
state: Cambridgeshire
Study officials:
affiliation: University of Cambridge
name: Charlotte K Boughton
role: PRINCIPAL_INVESTIGATOR
References: